<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">6487491</PMID>
        <DateCompleted>
            <Year>1984</Year>
            <Month>12</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>05</Month>
            <Day>11</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0306-5251</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>18</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1984</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of clinical pharmacology</Title>
                <ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The effect of acetylator phenotype on the disposition of aminoglutethimide.</ArticleTitle>
            <Pagination>
                <MedlinePgn>495-505</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Aminoglutethimide (AG) 500 mg was administered orally to four normal volunteers and eight patients undergoing treatment for metastatic breast cancer. In each subject the acetylator phenotype was established from the monoacetyldapsone (MADDS)/dapsone (DDS) ratio. Acetylaminoglutethimide (acetylAG) rapidly appeared in the plasma and its disposition paralleled that of AG. A close relationship (P less than 0.01) was observed between the acetyl AG/AG and MADDS/DDS ratio suggesting that AG may undergo polymorphic acetylation like DDS. AG half-life was 19.5 +/- 7.7 h in seven fast acetylators of DDS and 12.6 +/- 2.3 h in five slow acetylators and its apparent metabolic clearance was significantly (P less than 0.01) related to the acetylAG/AG ratio. Over 48 h the fast acetylators excreted 7.7 +/- 4.4% of the administered AG dose in the urine as unchanged AG as compared to 12.4 +/- 2.8% in slow acetylators. A much smaller fraction of the dose was excreted as acetylAG: 3.6 +/- 1.5% by fast and 1.9 +/- 1.0% by slow acetylators respectively. After 7 days treatment with AG at an accepted clinical dose regimen to the eight patients there were significant reductions in the half-lives of AG (P less than 0.01) and acetylAG (P less than 0.01) and a trend (0.1 greater than P greater than 0.05) towards reduction of the acetylAG/AG ratio which became significant (P less than 0.05) if the one patient on a known enzyme inducer was omitted. The mean apparent volume of distribution was not significantly (P greater than 0.1) altered but the mean apparent systemic clearance of AG was increased (P less than 0.05). These changes are attributed to auto-induction of oxidative enzymes involved in AG metabolism.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Adam</LastName>
                    <ForeName>A M</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rogers</LastName>
                    <ForeName>H J</ForeName>
                    <Initials>HJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Amiel</LastName>
                    <ForeName>S A</ForeName>
                    <Initials>SA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rubens</LastName>
                    <ForeName>R D</ForeName>
                    <Initials>RD</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Br J Clin Pharmacol</MedlineTA>
            <NlmUniqueID>7503323</NlmUniqueID>
            <ISSNLinking>0306-5251</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0O54ZQ14I9</RegistryNumber>
                <NameOfSubstance UI="D000616">Aminoglutethimide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000616" MajorTopicYN="N">Aminoglutethimide</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004790" MajorTopicYN="N">Enzyme Induction</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1984</Year>
                <Month>10</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1984</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1984</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6487491</ArticleId>
            <ArticleId IdType="pmc">PMC1463619</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1365-2125.1984.tb02497.x</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Pharmacokinet. 1979 Nov-Dec;4(6):401-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">391461</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Pharmacol. 1979 Nov-Dec;19(11-12):704-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">536467</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Pharmacol Ther. 1980 Dec;28(6):769-78</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7438692</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 1982 Jan;96(1):94-101</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7053713</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 1982 Aug;42(8 Suppl):3353s-3359s</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7083200</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 1982 Sep;46(3):340-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7126424</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Clin Pharmacol. 1982;23(6):523-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7160421</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Chem. 1983 Jan;26(1):50-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6827528</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 1983 Mar 26;1(8326 Pt 1):670-1</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6132036</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Clin Pharmacol. 1983 Jul;16(1):27-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6882620</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biomed Mass Spectrom. 1983 Nov;10(11):620-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6689274</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharm Sci. 1981 Sep;70(9):1040-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6101151</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Lab Clin Med. 1964 Mar;63:394-403</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14164493</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Endocrinol Metab. 1967 Apr;27(4):481-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">4290077</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Endocrinol Metab. 1967 Sep;27(9):1239-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">4292247</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Pharmacol Ther. 1971 Mar-Apr;12(2):225-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">5554939</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharm Pharmacol. 1972 Dec;24:Suppl:150P</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">4144875</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Clin Pharmacol. 1978 Aug;6(2):185-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">678400</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Clin Pharmacol. 1978 Nov;6(5):421-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">728285</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Clin Pharmacol. 1978 Dec;6(6):525-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">728322</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>